Sponsored by
Data Demonstrates RAV12's Anti-Tumor Activity
SOUTH SAN FRANCISCO, Calif., April 18 /PRNewswire/ -- Raven
biotechnologies, inc. announced today the company is presenting preclinical
data on RAV12, its lead clinical stage therapeutic monoclonal antibody for GI
and other adenocarcinoma related cancers. The data is being presented at the
American Association for Cancer Research (AACR) annual meeting April 16-20 in
Anaheim, California.
Raven scientists will present the following abstract: "The Monoclonal
Antibody RAV12 Induces Oncotic Cell Death in vitro and Exhibits Potent
Anti-tumor Activity in Human Tumor Xenografts." (Abstract # 558), D. Loo,
et al.
"This data supports the IND application for RAV12 for the treatment of
advanced stage adenocarcinomas which we filed last November," said Jennie
Mather, PhD, President and CEO of Raven. "The data presented at AACR provides
further support for the potential of RAV12 for the treatment of GI cancers and
validates the power of our discovery platform, which is focused exclusively on
therapeutic antibodies for cancer." The IND application was accepted by the
FDA and Raven commenced its phase 1 clinical in December 2004.
About Raven
Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held
biotechnology company initially focused on the development of monoclonal
antibodies therapeutics for treating cancer. Raven's lead product candidate,
RAV12, targets adenocarcinomas of the GI tract and is in an on-going phase 1
clinical trial. Raven's proprietary discovery process simultaneously
identifies novel cell-surface drug targets and the antibody therapeutics to
regulate them. Raven's integrated approach is based on proprietary, human
tissue-specific progenitor and tumor stem cell lines developed at Raven, plus
proprietary methods optimized for producing MAbs targeting cell-surface
proteins. This platform rapidly identifies target antigens and therapeutic
candidates in their native configuration in the intact cell membrane. The
Company has identified candidate therapeutic MAbs for many cancer indications
including lung, colon, pancreatic, prostate, breast, brain, and ovarian
cancer.
SOURCE Raven biotechnologies, inc.
Web Site: http://www.ravenbio.com